A Multicenter Phase II Study of Second‐Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First‐Line Sorafenib Monotherapy

LESSONS LEARNED: For patients with advanced hepatocellular carcinoma after failure of first‐line sorafenib monotherapy, second‐line axitinib provides modest efficacy with tolerable toxicity. The discrepant tumor responses and survival outcomes in trials using axitinib as salvage therapy highlight th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Lin, Zhong‐Zhe, Chen, Bang‐Bin, Hung, Yi‐Ping, Huang, Po‐Hsiang, Shen, Ying‐Chun, Shao, Yu‐Yun, Hsu, Chih‐Hung, Cheng, Ann‐Lii, Lee, Rheun‐Chuan, Chao, Yee, Hsu, Chiun
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Trial Results
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485356/
https://ncbi.nlm.nih.gov/pubmed/32271494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0143
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares